Blood CD 9 + B Cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation - Archive ouverte HAL Access content directly
Journal Articles American Journal of Transplantation Year : 2019

Blood CD 9 + B Cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation

Carole Brosseau
  • Function : Author
  • PersonId : 924198
Richard Danger
Durand Maxim
  • Function : Author
Eugénie Durand
  • Function : Author
Aurore Foureau
  • Function : Author
Philippe Lacoste
  • Function : Author
Adrien Tissot
  • Function : Author
Antoine Roux
  • Function : Author
Romain Kessler
  • Function : Author
Sacha Mussot
  • Function : Author
Claire Dromer
  • Function : Author
Olivier Brugière
  • Function : Author
Mornex Jean-Francois
  • Function : Author
Romain Guillemain
  • Function : Author
Joana Claustre
  • Function : Author
Antoine Magnan
  • Function : Author
Sophie Brouard
  • Function : Author

Abstract

Bronchiolitis obliterans syndrome is the main limitation for long-term survival after lung transplantation. Some specific B cell populations are associated with long-term graft acceptance. We aimed to monitor the B cell profile during early development of bronchiolitis obliterans syndrome after lung transplantation. The B cell longitudinal profile was analyzed in peripheral blood mononuclear cells from patients with bronchiolitis obliterans syndrome and patients who remained stable over 3 years of follow-up. CD24(hi)CD38(hi) transitional B cells were increased in stable patients only, and reached a peak 24 months after transplantation, whereas they remained unchanged in patients who developed a bronchiolitis obliterans syndrome. These CD24(hi)CD38(hi) transitional B cells specifically secrete IL-10 and express CD9. Thus, patients with a total CD9(+) B cell frequency below 6.6% displayed significantly higher incidence of bronchiolitis obliterans syndrome (AUC = 0.836, PPV = 0.75, NPV = 1). These data are the first to associate IL-10-secreting CD24(hi)CD38(hi) transitional B cells expressing CD9 with better allograft outcome in lung transplant recipients. CD9-expressing B cells appear as a contributor to a favorable environment essential for the maintenance of long-term stable graft function and as a new predictive biomarker of bronchiolitis obliterans syndrome-free survival.

Dates and versions

hal-02263607 , version 1 (05-08-2019)

Identifiers

Cite

Carole Brosseau, Richard Danger, Durand Maxim, Eugénie Durand, Aurore Foureau, et al.. Blood CD 9 + B Cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation. American Journal of Transplantation, 2019, 19 (11), pp.3162-3175. ⟨10.1111/ajt.15532⟩. ⟨hal-02263607⟩

Collections

CNRS UNIV-AMU
20 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More